Alireza Ray Rezaie

US Patent:

6794493, Sep 21, 2004

Filed:

Apr 6, 2001

Appl. No.:

09/828592

Inventors:

Timothy Walston - Fitchburg WI
Scott Cooper - Holmen WI
Alireza Rezaie - Eureka MO

Assignee:

WiSys Technology Foundation, Inc. - Madison WI

International Classification:

A61K 3514

US Classification:

530381, 530384, 530350, 435 13, 424 9464

Abstract:

Mutant antithrombin modified to carry a more positive charge in the H-helix is provided. The modified antithrombin modulates the activities of thrombin, and extends the bioavailability of factor VIII.

US Patent:

7247453, Jul 24, 2007

Filed:

Jun 10, 1994

Appl. No.:

08/259321

Inventors:

Alireza Rezaie - Moore OK, US
Charles T. Esmon - Oklahoma City OK, US

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK

International Classification:

C12P 21/08
A61K 39/395
C07K 16/18

US Classification:

435 696, 435 701, 435 712, 4241331, 4241411, 5303871, 5303873, 5303881

Abstract:

A Ca dependent recombinant antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C has been constructed. The antibody does not bind to Activated Protein C and can be used to inhibit activation of Protein C by thrombin-thrombomodulin, in purification of Protein C, and in treatment of tumors.

US Patent:

7785857, Aug 31, 2010

Filed:

Aug 30, 2007

Appl. No.:

11/848080

Inventors:

Alireza R. Rezaie - Eureka MO, US
Likui Yang - St. Louis MO, US

Assignee:

Saint Louis University - Saint Louis MO

International Classification:

C12N 9/64

US Classification:

435226

Abstract:

This invention relates to a novel form of protein C or activated protein C. More specifically, the invention is directed to a variant of protein C that is activated at a higher rate than wild-type or other variants and produces an activated protein C with reduced anticoagulant properties while retaining the protective anti-inflammatory and anti-apoptotic properties of wild-type activated protein C. This novel APC variant will be beneficial for treating inflammatory and apoptotic disorders with a reduced risk for bleeding.

US Patent:

20100247511, Sep 30, 2010

Filed:

Jun 8, 2010

Appl. No.:

12/796623

Inventors:

ALIREZA R. REZAIE - EUREKA MO, US
LIKUI YANG - ST. LOUIS MO, US

Assignee:

SAINT LOUIS UNIVERSITY - SAINT LOUIS MO

International Classification:

A61K 38/48
A61P 29/00
A61P 25/00
A61P 25/28
A61P 9/10

US Classification:

424 9464

Abstract:

This invention relates to a novel form of protein C or activated protein C. More specifically, the invention is directed to a variant of protein C that is activated at a higher rate than wild-type or other variants and produces an activated protein C with reduced anticoagulant properties while retaining the protective anti-inflammatory and anti-apoptotic properties of wild-type activated protein C. This novel APC variant will be beneficial for treating inflammatory and apoptotic disorders with a reduced risk for bleeding.

US Patent:

20130071375, Mar 21, 2013

Filed:

Aug 21, 2012

Appl. No.:

13/591091

Inventors:

Jong-Sup Bae - Daegu, KR
Alireza R. Rezaie - Eureka MO, US

Assignee:

SAINT LOUIS UNIVERSITY - St. Louis MO

International Classification:

C07K 19/00

US Classification:

424 9464, 435188

Abstract:

The present invention provides methods for treating sepsis comprising administering to an individual an effective amount of a chimeric protein.

US Patent:

52985997, Mar 29, 1994

Filed:

Jan 3, 1992

Appl. No.:

7/816679

Inventors:

Alireza Rezaie - Moore OK
Charles T. Esmon - Oklahoma City OK
James H. Morrissey - Oklahoma City OK

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK

International Classification:

C07K 1300

US Classification:

530350

Abstract:

A method is disclosed to make any protein in a form that can be isolated rapidly from a solution using a specific monoclonal antibody designated "HPC-4". It has now been determined that it is possible to form a fusion protein of the epitope with a protein to be isolated, and isolate the protein using HPC-4-based affinity chromatography. In the preferred embodiment, a specific protease cleavage site is inserted between the epitope and the protein so that the epitope can be easily removed from the isolated protein. In an example, a functionally active soluble tissue factor including the twelve amino acid epitope recognized in combination with calcium by HPC-4 and a factor Xa cleavage site was expressed from a vector inserted into a procaryotic expression system. The recombinant tissue factor can be rapidly isolated in a single chromatographic step using the HPC-4 monoclonal antibody immobilized on a suitable substrate. Once isolated, the Protein C epitope is removed by cleavage with factor Xa, leaving the functionally active, soluble tissue factor.